ENDONOVO THERAPEUTICS, INC. Total Revenue

• ENDONOVO THERAPEUTICS, INC. showed an increase of +85.2% in Total Revenue from 2021 to 2022.
• This data is from ENDONOVO THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on April 17, 2023.
• XBRL data for this metric is available from 2010 to 2022 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2011: $0.00 | Q1 2012: $1.7 thousand | Q2 2012: $8.1 thousand | Q3 2012: $7.2 thousand | Q3 2013: $0.00 | Q1 2018: $7.0 thousand | Q1 2018: $7.0 thousand | Q2 2018: $12.9 thousand | Q2 2018: $12.9 thousand | Q3 2018: $21.3 thousand | Q3 2018: $21.3 thousand | Q1 2019: $45.0 thousand | Q2 2019: $62.7 thousand | Q3 2019: $54.0 thousand | Q1 2020: $69.7 thousand | Q2 2020: $44.6 thousand | Q3 2020: $40.0 thousand | Q1 2021: $34.7 thousand | Q2 2021: $30.3 thousand | Q3 2021: $7.8 thousand | Q1 2022: $2.3 thousand | Q2 2022: $650.00 | Q3 2022: $11.0 thousand | Q1 2023: $87.5 thousand | Q2 2023: $45.2 thousand | Q3 2023: $1.5 thousand.
• Over the full 7 years of available data (2010 to 2022), ENDONOVO THERAPEUTICS, INC.'s Total Revenue has grown by 164.4%.
• Historical annual values: Fiscal year 2022: $135.4 thousand | Fiscal year 2021: $73.1 thousand | Fiscal year 2020: $165.8 thousand | Fiscal year 2019: $310.2 thousand | Fiscal year 2018: $83.3 thousand | Fiscal year 2011: $45.5 thousand | Fiscal year 2010: $51.2 thousand.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026